Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) PE Ratio: 28.91

Is Medpace Holdings, Inc.’s P/E ratio high or low?

Medpace Holdings, Inc.'s P/E ratio of 28.91 is 13% below its 5-year average of 33.11, near the low end of its 5-year range (21.55–47.18).

As of Friday, June 19, 2026. 14.85% below its 12-month average of 33.95.

PE Ratio (28.91) = Close Price ($460.20) / Diluted TTM EPS ($15.92)

MEDP PE Ratio Chart

MEDP PE Ratio
28.91+25.10% 1Y
Zoom

MEDP Average PE Ratio Chart

MEDP Current vs Average PE Ratio Chart

MEDP PE Ratio Metrics

PE RATIO

28.91

PE RATIO AVG TTM

33.95

PE RATIO AVG 3Y

33.23

PE RATIO AVG 5Y

33.11

PE RATIO AVG 10Y

36.13

PE RATIO AVG 15Y

N/A

PE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-14.85%

CURRENT VS 3Y AVG

-13.00%

CURRENT VS 5Y AVG

-12.69%

CURRENT VS 10Y AVG

-19.97%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MEDP Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
Medpace Holdings, Inc. (MEDP)$13.14B28.9133.9533.2333.11
Solventum Corporation (SOLV)vs ›$13.06B9.2318.3817.0017.00
Align Technology, Inc. (ALGN)vs ›$13.04B30.5529.2142.5247.46
DaVita Inc. (DVA)vs ›$13.34B20.9214.5715.8814.84
The Cooper Companies, Inc. (COO)vs ›$12.85B55.8637.4547.6631.45
Revvity, Inc. (RVTY)vs ›$11.16B47.6243.9741.0633.76
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37BN/A33.4814.6325.08
Baxter International Inc. (BAX)vs ›$10.27BN/A44.5334.4137.43
Hologic, Inc. (HOLX)vs ›$16.97B31.6728.1230.0822.83
Zimmer Biomet Holdings, Inc. (ZBH)vs ›$17.02B22.8523.4829.9147.60

P/E vs. its own history

At 28.9, P/E is cheaper than usual, sitting higher than 19% of its 10-year history.

10-year low

21.6

median

35.3

10-year high

315.6

cheaperricher

P/E Comparison

Trailing P/E

28.9

Forward P/E

24.8

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$460.20

÷

Forward EPS (Est.)

$18.55

=

Forward P/E

24.80

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Medpace Holdings, Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Medpace Holdings, Inc. PE Ratio FAQ

What is the P/E ratio for Medpace Holdings, Inc. (MEDP)?
The P/E ratio for MEDP stock is 28.91.
Is Medpace Holdings, Inc.'s P/E ratio high or low?
Medpace Holdings, Inc.'s P/E ratio of 28.91 is 13% below its 5-year average of 33.11, near the low end of its 5-year range (21.55–47.18).
What is the TTM average P/E ratio for Medpace Holdings, Inc. (MEDP)?
The TTM average P/E ratio for MEDP stock is 33.95.
What is the 3Y average P/E ratio for Medpace Holdings, Inc. (MEDP)?
The 3Y average P/E ratio for MEDP stock is 33.23.
What is the 5Y average P/E ratio for Medpace Holdings, Inc. (MEDP)?
The 5Y average P/E ratio for MEDP stock is 33.11.
What is the 10Y average P/E ratio for Medpace Holdings, Inc. (MEDP)?
The 10Y average P/E ratio for MEDP stock is 36.13.

Medpace Holdings, Inc. PE Ratio History

DATEPE RATIO
2026-06-1828.91
2026-06-1728.71
2026-06-1628.99
2026-06-1529.37
2026-06-1229.36
2026-06-1129.84
2026-06-1029.25
2026-06-0929.32
2026-06-0828.76
2026-06-0528.53
2026-06-0428.81
2026-06-0328.32
2026-06-0227.99
2026-06-0128.36
2026-05-2928.08
2026-05-2828.15
2026-05-2726.88
2026-05-2626.95
2026-05-2227.19
2026-05-2127.02
2026-05-2026.50
2026-05-1926.38
2026-05-1826.42
2026-05-1526.08
2026-05-1426.33
2026-05-1326.62
2026-05-1226.37
2026-05-1126.21
2026-05-0826.63
2026-05-0726.93
2026-05-0626.81
2026-05-0527.03
2026-05-0426.19
2026-05-0126.23
2026-04-3026.30
2026-04-2925.98
2026-04-2825.73
2026-04-2726.47
2026-04-2425.79
2026-04-2324.71
2026-04-2233.21
2026-04-2133.63
2026-04-2034.52
2026-04-1734.00
2026-04-1633.68
2026-04-1533.87
2026-04-1433.96
2026-04-1332.74
2026-04-1032.24
2026-04-0932.76
2026-04-0834.01
2026-04-0733.21
2026-04-0632.40
2026-04-0232.55
2026-04-0131.97
2026-03-3131.36
2026-03-3030.07
2026-03-2729.47
2026-03-2630.48
2026-03-2530.49
2026-03-2430.09
2026-03-2329.85
2026-03-2029.56
2026-03-1930.11
2026-03-1829.71
2026-03-1729.73
2026-03-1629.63
2026-03-1329.42
2026-03-1228.99
2026-03-1131.20
2026-03-1030.49
2026-03-0931.26
2026-03-0630.74
2026-03-0530.66
2026-03-0430.43
2026-03-0330.40
2026-03-0229.88
2026-02-2729.51
2026-02-2629.20
2026-02-2528.61
2026-02-2428.88
2026-02-2329.06
2026-02-2029.64
2026-02-1929.16
2026-02-1829.14
2026-02-1727.97
2026-02-1327.96
2026-02-1227.17
2026-02-1127.69
2026-02-1029.13
2026-02-0937.06
2026-02-0637.88
2026-02-0537.82
2026-02-0439.24
2026-02-0339.73
2026-02-0241.10
2026-01-3040.70
2026-01-2941.44
2026-01-2841.78
2026-01-2742.09
2026-01-2642.07
2026-01-2341.09
2026-01-2242.37
2026-01-2143.37
2026-01-2042.10
2026-01-1642.69
2026-01-1543.19
2026-01-1443.08
2026-01-1342.52
2026-01-1241.87
2026-01-0941.58
2026-01-0841.93
2026-01-0742.84
2026-01-0642.55
2026-01-0541.01
2026-01-0239.90
2025-12-3139.25
2025-12-3039.75
2025-12-2939.83
2025-12-2639.66
2025-12-2439.96
2025-12-2339.81
2025-12-2239.94
2025-12-1939.72
2025-12-1839.15
2025-12-1738.93
2025-12-1639.05
2025-12-1539.07
2025-12-1238.99
2025-12-1139.56
2025-12-1039.19
2025-12-0938.02
2025-12-0838.38
2025-12-0538.30
2025-12-0438.07
2025-12-0340.29
2025-12-0240.79
2025-12-0141.09
2025-11-2841.40
2025-11-2642.39
2025-11-2542.75
2025-11-2443.22
2025-11-2141.36
2025-11-2040.96
2025-11-1941.38
2025-11-1841.24
2025-11-1740.93
2025-11-1441.24
2025-11-1341.32
2025-11-1241.76
2025-11-1142.12
2025-11-1041.96
2025-11-0741.17
2025-11-0641.38
2025-11-0541.85
2025-11-0441.55
2025-11-0341.51
2025-10-3140.87
2025-10-3040.56
2025-10-2940.85
2025-10-2840.57
2025-10-2741.68
2025-10-2442.29
2025-10-2341.69
2025-10-2240.65
2025-10-2140.57
2025-10-2040.48
2025-10-1739.26
2025-10-1638.75
2025-10-1538.24
2025-10-1438.43
2025-10-1339.21
2025-10-1037.27
2025-10-0938.56
2025-10-0839.48
2025-10-0739.54
2025-10-0639.43
2025-10-0339.59
2025-10-0239.86
2025-10-0140.44
2025-09-3038.23
2025-09-2937.23
2025-09-2636.94
2025-09-2536.28
2025-09-2436.98
2025-09-2336.89
2025-09-2237.03
2025-09-1937.07
2025-09-1837.32
2025-09-1737.01
2025-09-1636.49
2025-09-1536.91
2025-09-1236.48
2025-09-1137.00
2025-09-1035.44
2025-09-0936.10
2025-09-0836.59
2025-09-0536.21
2025-09-0435.86
2025-09-0335.78
2025-09-0235.19
2025-08-2935.35
2025-08-2835.16
2025-08-2735.20
2025-08-2634.89
2025-08-2534.71
2025-08-2234.47
2025-08-2133.71
2025-08-2034.63
2025-08-1934.36
2025-08-1834.42
2025-08-1534.04
2025-08-1434.10
2025-08-1334.80
2025-08-1234.15
2025-08-1133.44
2025-08-0832.29
2025-08-0731.88
2025-08-0632.00
2025-08-0532.44
2025-08-0432.15
2025-08-0131.46
2025-07-3131.76
2025-07-3032.55
2025-07-2933.30
2025-07-2833.68
2025-07-2533.27
2025-07-2433.88
2025-07-2332.52
2025-07-2235.52
2025-07-2123.58
2025-07-1823.81
2025-07-1724.36
2025-07-1624.03
2025-07-1523.87
2025-07-1424.45
2025-07-1124.69
2025-07-1025.06
2025-07-0924.50
2025-07-0824.62
2025-07-0724.34
2025-07-0324.54
2025-07-0224.89
2025-07-0124.51
2025-06-3023.96
2025-06-2723.72
2025-06-2623.42
2025-06-2523.75
2025-06-2424.07
2025-06-2323.56
2025-06-2023.62
2025-06-1823.11
2025-06-1722.74
2025-06-1622.98
2025-06-1322.77
2025-06-1223.21
2025-06-1123.08
2025-06-1023.35
2025-06-0922.77
2025-06-0622.63

Showing the most recent 260 of 2,418 data points. The chart above shows the full history.

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle